Videos

Results indicated that vaccine response with the standard regimen dramatically low; however, both novel strategies were able to significantly improve response.

“These are people with autoimmune conditions who are taking immunomodulatory drugs that affect their immune system,” Mudano emphasized. “It's been shown that they may have worse outcomes if they do get COVID. So, it's important that they know that they really need this vaccine.”

Nowell emphasized that simple changes, such as targeted walking goals and meditative breathing, are low energy and low cost, yet extremely effective.

“There's a real interest and need for wellness programs out there among people living with psoriatic arthritis. This is something that matters to them even more now living with a chronic disease.”

Two methods of identifying patients with axPsA, including an artificial intelligence approach, reported nearly identical outcomes with positive improvement of symptoms of axPsA.

Investigators used interviews, performed in a patient’s preferred language and transcribed verbatim, to better uncover and understand what matters most to the Hispanic population.

“It’s very possible to reach the Hispanic community and to go above and beyond what is currently being done, which is very little in terms of supporting them and giving them the tools that they need to create to have a better quality of life."

Gout, if left untreated, can lead to flares that can increase the likelihood of depression and anxiety.

Wipfler emphasized that most of the delays have been associated with pharmacies needing to confirm the purpose of the prescription with the provider.

“We imagine that the rate of problems [accessing methotrexate] is going to be much higher in higher-risk populations," Wipfler explained.

Hamilton and his team aim to reduce intensive and often unnecessary screening, including weekly fetal cardiac ultrasounds, via autoantibody identification.

The number of autoantibodies and congenital heart block pregnancies expanded to approximately 30 different autoantibodies to different targets near term.

John Cush, MD, discusses his CCR West presentation “Rheumatology Year in Review: 2022.” 

John Cush, MD, discusses his presentation “Rheumatoid Arthritis: How Early is Too Early to Diagnose and Treat?”

Dr. Veronica Anwuri discusses how apremilast (Otezla), the first oral, non biologic treatment option for plaque psoriasis can address the systemic pain associated with psoriatic arthritis.

Drs. Anne E. Winkler and Kristi V. Mizelle share practice pearls to optimize the management of patients of patients diagnosed with lupus.

Experts in rheumatology provide an overview of novel treatment options currently under investigation for the treatment of systemic lupus erythematosus and lupus nephritis.

Kristi V. Mizelle, MD, MPH, FACR comments on long term efficacy data on the use of biologics in lupus, with a focus on preventing organ damage.

Anne E. Winkler, MD, PhD, MACP shares her approach to treatment in patients with lupus post treatment with immunosuppressants with a focus on treatment sequencing.

Drs Anne E. Winkler and Kristi V. Mizelle explore relevant treatment options for a patient with lupus nephritis and highlight efficacy and safety considerations.

Terence Rooney, MD, discusses the ongoing STAR study in depth and the potential of guselkumab to improve axial psoriatic arthritis.

An expert in lupus management provides insight into her treatment approach for a 24-year-old African American female diagnosed with lupus nephritis.

Lupus Case Scenario: Patient History and Presentation

The highly encouraging results of the small study may lead to a new therapeutic approach in lupus. However, long-term safety and efficacy need to be evaluated in a larger cohort.

Drs Orrin M. Troum and Jeff R. Peterson discuss infusion reactions associated with pegloticase and the impact of immunomodulators when used with pegloticase in gout.

Orrin M. Troum, MD, and Jeff R. Peterson, MD, discuss challenges with gout treatment.

Orrin M. Troum, MD, discusses methods and results of the MIRROR study in gout.

The Rheumatology Research Foundation has recently announced a grant, called the Community Practice Innovation Award, which focuses on supporting rheumatology practitioners to conduct their crucial, and potentially life-changing, research.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, address the importance of clinician confidence in biosimilars.

Anne E. Winkler, MD, PhD, MACP and Kristi V. Mizelle, MD, MPH, FACR hypothesize about the role and future of a treat to target approach in patients with lupus.